Why was melphalan/melphalan for injection withdrawn from China?

Melphalan for injectionThe withdrawal of Melphalan flufenamide from China was mainly affected by various factors. First of all, the clinical application effect and safety of drugs are the focus of regulatory authorities. Once on the market, a drug's efficacy and side effects are continuously monitored and evaluated. If safety issues are discovered during actual use or the efficacy is not as good as expected, the drug may be withdrawn. In addition, the market demand for drugs is also an important factor. If the demand for a certain drug is low in the market, the manufacturer may consider stopping production to avoid wasting resources.

Second, changes in policies and regulations may also affect drug sales. Domestic drug regulatory agencies regularly review drugs on the market to ensure that they comply with the latest drug standards and regulatory requirements. If injectable melphalan fails to meet these new standards or encounters obstacles in the approval process, it could be forced to withdraw from the market. At the same time, the country's management of anti-tumor drugs is becoming more and more strict, and the relevant review procedures are becoming increasingly complex, which makes it difficult for some drugs to remain on the market.

In addition, the intensification of market competition is also a major reason. With the rapid development of biopharmaceutical technology, new anti-cancer drugs are emerging one after another, and many new treatments and alternative drugs have emerged on the market. These new drugs may be superior to traditional drugs in terms of efficacy, safety, and patient experience, leading to a gradual decrease in the market share of older drugs. In this case, drugs that originally relied on market demand may withdraw from the market due to lack of competitiveness.

If the company faces difficulties in R&D, production, and sales, such as insufficient funds and substandard production processes, it may also lead to the withdrawal of the drug. As companies continue to evaluate their product pipelines, they may choose to focus on drugs with greater market potential and abandon some products that have poor sales or low profitability.